Platelets, Thrombosis and Cancer > Laboratory People
Dr Vivien Chen MBBS (University Medal, University of Sydney), BA PhD, FRACP, FRCPA
Laboratory Leader - Platelet, Thrombosis and Cancer Research Lab
ANZAC Research Institute
Concord Repatriation General Hospital
Dr. Vivien Chen is a haematologist with a research and clinical focus in coagulation disorders. She is staff specialist haematologist at Concord Repatriation and General Hospital where she leads the thrombosis clinic. Dr Chen heads the Platelet and Thrombosis Research Laboratory alongside the Vascular Biology Group at the ANZAC Research Institute where her work focuses on platelet function in cardiovascular thrombotic disorders and the interface between malignancy and blood clotting. Dr Chen completed her PhD at the University of New South Wales, Australia on the molecular mechanism of tissue factor activation, post-doctoral fellowship with Professors Bruce and Barbara Furie at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston USA before establishing her research group in Sydney Australia. Her current research focus is the biology of the procoagulant platelets and the involvement of cell death pathways in the formation of platelet subsets. Translational focus is on the predictive and prognostic role of these platelets in vascular biology as well as strategies to reduce the impact of these pathological platelets in disease states such as coronary artery disease, stroke, myeloproliferative disease and sepsis. Dr Chen’s clinical research focuses on venous thrombo-embolism, in particular, on the predictors and management of cancer associated thrombosis.
Dr Helena Liang completed her PhD at the University of Sydney, investigating the molecular mechanism of various inherited platelet disorders in human patients. Following her graduation, she did her postdoctoral training first at the Lowy Cancer Research Center UNSW, where she studied the de-encryption mechanism of tissue factor in blood coagulation; and subsequently at the Blood Centre of Wisconsin in U.S.A., where she studied the molecular mechanism of activated protein C (aPC) in the treatment of sepsis, and the roles of the protein C system in embryonic development and thrombosis. After returning to Australia, Dr Liang continued to study the cellular mechanism of aPC in other chronic inflammatory diseases at the Kolling Research Institute, before joining the Platelet and Thrombosis Group at the ANZAC Research Institute in October 2016, to investigate the role of platelet subpopulations in pathological thrombus formation, using a combination of ex vivo flow cytometry and in vivo intravital microscopy, as well as super-resolution microscopy techniques.
Morgane Bourcy obtained her PhD degree in Biomedical and Pharmaceutical sciences at University of Liège (Belgium) in 2016. She performed her thesis in the laboratory of Tumor and Development Biology (GIGA) within the research group of Dr. Gilles Christine. Her research focused on the acquisition of procoagulant properties by circulating tumor cells during epithelial to mesenchymal processes (EMT). During these years, she acquired knowledge on EMT and metastasis formation. She then joined the Platelet and Thrombosis Research Laboratory at the ANZAC Research Institute at the end of 2016 with an aim to improve her expertise in the field of coagulation.